Intravitreal Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy
- 1 December 2019
- journal article
- research article
- Published by Elsevier in Ophthalmology Retina
- Vol. 3 (12) , 1076-1086
Abstract
No abstract availableKeywords
Funding Information
- Regeneron
This publication has 27 references indexed in Scilit:
- Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic RetinopathyJAMA Ophthalmology, 2018
- Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision ImpairmentJAMA Ophthalmology, 2018
- Distribution of Nonperfusion Area on Ultra-widefield Fluorescein Angiography in Eyes With Diabetic Macular Edema: DAVE StudyAmerican Journal of Ophthalmology, 2017
- Change in Diabetic Retinopathy Through 2 YearsJAMA Ophthalmology, 2017
- Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic RetinopathyJAMA, 2015
- Intravitreal Aflibercept for Diabetic Macular EdemaOphthalmology, 2015
- Long-term Effects of Therapy with Ranibizumab on Diabetic Retinopathy Severity and Baseline Risk Factors for Worsening RetinopathyOphthalmology, 2015
- Neutralization of Vascular Endothelial Growth Factor Slows Progression of Retinal Nonperfusion in Patients with Diabetic Macular EdemaOphthalmology, 2014
- Long-term Effects of Ranibizumab on Diabetic Retinopathy Severity and ProgressionArchives of Ophthalmology (1950), 2012
- Intravitreal Bevacizumab (Avastin) in the Treatment of Proliferative Diabetic RetinopathyOphthalmology, 2006